Search filters

List of works by Neill J Liptrott

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation

scientific article

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

scientific article published on January 2012

Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach

scientific article published on 16 March 2018

Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry

scientific article published on 16 October 2008

Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches.

scientific article

Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis

scientific article published on 21 October 2020

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

scientific article published on 06 May 2020

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

scientific article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

scientific article published on February 2010

IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients

article

In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells

scientific article published on 05 August 2020

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

scientific article published on 21 June 2013

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

scientific article

Nanomedicines for HIV therapy

scientific article

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a ‘mixed matrix’

article by Neill J Liptrott et al published November 2014 in Nanomedicine

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

scientific article published on December 15, 2011

Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients

scientific article published on 11 October 2010

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

scientific article published on 22 April 2020

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

scientific article

Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro

scientific article published on 03 September 2013

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.

scientific article published on 20 January 2009

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?

scientific article published on 08 February 2011